Repatha
Q2 2026 sales rose 37% to $953 million, the biggest growth driver among Amgen's large products.
The numbers
What it is
PCSK9 inhibitor that lowers LDL cholesterol. It is Amgen's main cardiovascular medicine, and new VESALIUS-CV analyses were presented at the ESC Congress in August 2026.
Why it matters to the stock. Repatha is one of the largest growth engines in Amgen's portfolio. Its trend sets how quickly Amgen can offset the decline in Prolia.
News
Repatha linked to 20% lower all-cause mortality in VESALIUS-CV analysis at ESC
Amgen presented a pre-specified secondary analysis of the VESALIUS-CV trial at ESC Congress 2026 on August 31, 2026, showing a 20% reduction in all-cause mortality with Repatha.
AMUNDSEN: immediate evolocumab after heart attack lifts LDL goal rates, misses one-year outcome
The AMUNDSEN study, presented at ESC Congress 2026 in Munich, tested immediate evolocumab before PCI in 2,161 patients with acute heart attack.
Amgen's 2026 outlook: $38.2B to $39.4B revenue and $22.30 to $23.50 non-GAAP EPS
Alongside its second-quarter results, Amgen set full-year 2026 guidance of $38.2 billion to $39.4 billion in total revenues, non-GAAP diluted EPS of $22.30 to $23.50, and GAAP diluted EPS of $15.80 to $17.08.
EMA committee backs broader Repatha use before a first heart attack or stroke
The European Medicines Agency's CHMP adopted a positive opinion on July 29, 2026 for Repatha in adults with established or high-risk atherosclerotic cardiovascular disease, to reduce cardiovascular risk by lowering LDL cholesterol.
Amgen Q1 2026 revenue rises 6% to $8.6 billion; full-year guidance lifted
Amgen reported first-quarter 2026 total revenue of $8.6 billion, up 6%, and non-GAAP EPS of $5.15 against $4.90 a year earlier.